CD274 and neoplasm: Individual tumor sizes (fold-change) and ORR, as shown in Figure 4E, indicated that anti-PD-L1 antibody combined with regorafenib plus chidamide-k30 achieved 89% ORR, whereas treatment with anti-CTLA-4 antibody combined with cabozantinib plus chidamide-k30 achieved 90% ORR; these two regimens were superior to the other regimens.